Semaglutide Forms Explained: Tablets vs GLP-1 Injections

Explore the different semaglutide forms including GLP-1 injections and tablets, and how each may support type 2 diabetes management and metabolic health goals.

Key takeaways
  • Semaglutide forms include: once-weekly GLP-1 injections (Ozempic®, Wegovy®) and a once-daily tablet (Rybelsus®).
  • FDA-approved indications: Ozempic® and Rybelsus® are approved for type 2 diabetes. Wegovy® is approved for chronic weight management in individuals with obesity or overweight with a related medical condition.
  • GLP-1 injections may deliver greater clinical weight loss outcomes than oral forms in certain patient populations, based on current clinical trials¹.
  • Oral semaglutide requires precise dosing conditions for absorption (e.g., fasting before and after dosing).
  • All semaglutide products must be prescribed by a licensed healthcare provider and dispensed by regulated pharmacies.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

What Is Semaglutide?

Semaglutide is part of a class of medications called GLP-1 receptor agonists. These compounds mimic the GLP-1 hormone, which may support healthy blood sugar regulation by:

  • Stimulating insulin release in response to elevated blood glucose
  • Suppressing excess glucagon secretion
  • Slowing gastric emptying
  • Promoting a feeling of fullness after meals

Through these mechanisms, semaglutide may help individuals with type 2 diabetes manage glucose levels more effectively. In higher doses (as in Wegovy®), it may support long-term weight management for individuals with certain qualifying health conditions.

Overview of FDA-Approved Semaglutide Forms

Injectable GLP-1s

  • Ozempic®
    FDA-approved for: Type 2 diabetes
    Additional benefit: Reduces risk of major cardiovascular events in adults with type 2 diabetes and established heart disease
  • Wegovy®
    FDA-approved for: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition

Both injectables are administered subcutaneously once per week. Doses are typically escalated gradually to minimize gastrointestinal side effects.

Oral Semaglutide (Rybelsus®)

Rybelsus® is the first and only oral GLP-1 medication approved for type 2 diabetes. It uses an absorption enhancer to survive digestion and enter the bloodstream. While not FDA-approved for weight loss, some individuals may observe reduced appetite or eating behavior changes, which should be discussed with a healthcare provider.

Important Instructions:

  • Take on an empty stomach with ≤4 oz plain water
  • Wait 30+ minutes before eating, drinking, or taking other oral meds
  • Do not chew, split, or crush the tablet

Comparing Semaglutide Forms

Feature Injections (Ozempic®, Wegovy®) Tablets (Rybelsus®)
Frequency Once weekly Once daily
FDA Indications Diabetes (Ozempic®), Weight loss (Wegovy®) Diabetes only
Administration Subcutaneous injection Oral tablet with fasting protocol
Clinical Efficacy Typically higher weight loss and glucose reduction Effective for glucose control, gradual results
Ideal For Metabolic goals and adherence People avoiding injections

Semaglutide and Metabolic Health

Clinical trials suggest semaglutide’s potential to support metabolic function by modulating appetite, food cravings, and caloric intake. These effects may be more pronounced at higher, weight-loss-specific doses.

How Eden Helps You Access Semaglutide

Eden connects individuals with licensed healthcare providers who assess eligibility for GLP-1-based treatments, including semaglutide. We work with state-licensed pharmacies to ensure prescriptions are filled appropriately and safely.

Eden does not supply medications. All prescriptions are fulfilled by third-party licensed providers and pharmacies.

Conclusion

Understanding the differences between tablets and GLP-1 injections may help individuals choose the best semaglutide option with their healthcare provider.Metabolic health and glucose control may benefit from GLP-1 therapy when used safely, consistently, and with medical guidance.

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

Frequently asked questions

What’s the most effective form of semaglutide?

GLP-1 injectables (Ozempic®, Wegovy®) show stronger weight loss and glucose reduction in trials.

Can I switch from a GLP-1 injection to tablet?

Yes, under provider supervision.

Is semaglutide affordable without insurance?

Savings cards and manufacturer programs may reduce costs.

Does Eden provide semaglutide?

No. Eden connects you to licensed medical providers who may prescribe it if appropriate.

GLP-1 Treatments
Personalized doctor-led plans
As low as $196/mo*
Get started
Important safety information
Important safety information
Verified Customer
"I had an incredible experience, and the support that Eden provides is 10/10"
Kerstin
Verified Customer
“I had so many questions in the beginning, and both the doctor and customer support were so patient and thorough.”
Lane L.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

References

Belančić, A., & Al‐Sallami, H. S. (2025). Spotlight commentary: Changes in pharmacokinetics following significant weight loss. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16401

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity and Metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932

Canadian Agency for Drugs and Technologies in Health. (2022, December 1). Clinical review. Semaglutide (Wegovy) - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK601688/

Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025). Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA‐elderly). Diabetes Obesity and Metabolism. https://doi.org/10.1111/dom.16174

Kitsunai, H., Shinozaki, Y., Furusawa, S., Kitao, N., Ito, M., Kurihara, H., Oba-Yamamoto, C., Takeuchi, J., Nakamura, A., Takiyama, Y., & Nomoto, H. (2025). The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study. Pharmaceuticals, 18(1), 129. https://doi.org/10.3390/ph18010129

Koceva, A., Kozamernik, K. M., Janež, A., Herman, R., Ferjan, S., & Jensterle, M. (2025). Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review. Frontiers in Endocrinology, 15. https://doi.org/10.3389/fendo.2024.1528457

Wang, T., Cui, Y., & Liao, L. (2025). Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01689-1